In a patient with microangiopathic hemolytic anemia and a normal platelet count (~200,000/µL), should anticoagulation be started?

Anticoagulation in MAHA with Normal Platelet Count

In a patient with microangiopathic hemolytic anemia (MAHA) and a normal platelet count (~200,000/µL), anticoagulation should NOT be routinely started unless there is a specific thrombotic indication or underlying condition that requires it, such as antiphospholipid syndrome.

Key Decision Framework

The decision to anticoagulate depends entirely on identifying the underlying cause of MAHA, not the MAHA itself:

1. Rule Out TTP First

• MAHA with normal platelets makes TTP extremely unlikely, as TTP classically presents with severe thrombocytopenia (usually <30 × 10⁹/L) 1
• If TTP is suspected despite normal platelets, check ADAMTS-13 activity urgently
• The 2025 ISTH guidelines emphasize that TTP diagnosis requires severe ADAMTS-13 deficiency (<10%) in the proper clinical context 1

2. Identify Specific Thrombotic Conditions

Anticoagulation IS indicated if:

• Antiphospholipid syndrome (APS) is present: MAHA can occur with APS and lupus anticoagulant, where anticoagulation combined with plasma exchange has shown benefit 2
• Heparin-induced thrombocytopenia (HIT): Though this typically causes thrombocytopenia, it represents a prothrombotic state requiring alternative anticoagulation 3
• Active thrombosis is documented (DVT, PE, arterial thrombosis)

Anticoagulation is NOT indicated for:

• MAHA from DIC (requires treating underlying cause)
• MAHA from malignancy without thrombosis 4
• MAHA from pancreatitis 5
• MAHA from mechanical causes (prosthetic valves, devices)

3. Critical Caveat About Normal Platelets

Your patient's normal platelet count (~200,000/µL) is atypical for most thrombotic microangiopathies. This suggests:

• Not TTP (would have severe thrombocytopenia) 1
• Not HUS (typically has thrombocytopenia)
• Consider secondary MAHA from:
  • Malignancy (especially adenocarcinomas) 4
  • Severe hypertension
  • Mechanical hemolysis
  • Early/evolving process

Practical Algorithm

1. Check ADAMTS-13 activity - if <10%, treat as TTP (no anticoagulation needed; use plasma exchange, steroids, rituximab) 1, 5

2. Screen for APS - if positive lupus anticoagulant or anticardiolipin antibodies with thrombotic history, start anticoagulation 2

3. Image for thrombosis - if DVT/PE/arterial thrombosis found, anticoagulate per standard protocols

4. Evaluate for malignancy - especially GI adenocarcinomas if unexplained MAHA 4

5. If no thrombotic indication found - do NOT anticoagulate; focus on treating underlying cause

Important Pitfalls

• Do not reflexively anticoagulate all MAHA patients - bleeding risk exists even with normal platelets if there is active hemolysis and consumptive coagulopathy
• MAHA itself is not an indication for anticoagulation - it's a manifestation of various underlying conditions
• The 2025 ISTH guidelines note that antithrombotic agents in TTP should be used cautiously and only when specifically indicated 1
• Monitor coagulation-fibrinolysis markers if anticoagulation is started, as they can help assess disease activity and treatment response 2

Bottom line: The normal platelet count argues against primary thrombotic microangiopathy (TTP/HUS). Anticoagulate only if you identify a specific prothrombotic condition (APS, documented thrombosis) or if the underlying etiology specifically requires it. Otherwise, focus diagnostic efforts on finding the cause of MAHA.